The effects of curcumin supplementation on body mass index, body weight, and waist circumference in patients with nonalcoholic fatty liver disease: A systematic review and dose-response meta-analysis of randomized controlled trials.
Adult
Anthropometry
Body Mass Index
Body Weight
/ drug effects
Curcumin
/ administration & dosage
Dietary Supplements
/ analysis
Female
Humans
Male
Middle Aged
Non-alcoholic Fatty Liver Disease
/ drug therapy
Obesity
/ drug therapy
Randomized Controlled Trials as Topic
Waist Circumference
/ drug effects
Weight Loss
NAFLD
curcumin
meta-analysis
nonalcoholic fatty liver disease
systematic review
turmeric
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
08
05
2019
revised:
17
10
2019
accepted:
19
10
2019
pubmed:
5
12
2019
medline:
4
7
2020
entrez:
5
12
2019
Statut:
ppublish
Résumé
Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidity; its prevalence is elevating due to the rising epidemic of obesity. Several clinical trials have examined the effects of curcumin supplementation on anthropometric variables in NAFLD patients with inconclusive results. This dose-response meta-analysis aimed to evaluate the impact of curcumin supplementation on body mass index (BMI), body weight, and waist circumference (WC) in patients with NAFLD. A systematic review of the literature was conducted using PubMed/Medline, ISI Web of Science, Scopus, Cochrane Library, EMBASE, Google Scholar, Sid.ir, and Magiran.com to identify eligible studies up to March 2019. A meta-analysis of eligible studies was performed using the random-effects model to estimate the pooled effect size. Eight randomized controlled trials with 520 participants (curcumin group = 265 and placebo group = 255) were included. Supplementation dose and duration ranged from 70 to 3,000 mg/day and 8 to 12 weeks, respectively. Curcumin supplementation significantly reduced BMI (weighted mean difference [WMD] = -0.34 kg/m
Substances chimiques
Curcumin
IT942ZTH98
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
464-474Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. Mol Pharm, 4(6), 807-818. https://doi.org/10.1021/mp700113r
Borenstein, M., Hedges, L. V., Higgins, J. P., & Rothstein, H. R. (2011). Introduction to meta-analysis. John Wiley & Sons.
Bradford, P. G. (2013). Curcumin and obesity. Biofactors, 39(1), 78-87. https://doi.org/10.1002/biof.1074
Chashmniam, S., Mirhafez, S. R., Dehabeh, M., Hariri, M., Azimi Nezhad, M., & Nobakht, M. G. B. F. (2019). A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr.. https://doi.org/10.1038/s41430-018-0386-5
Cicero, A. F. G., Colletti, A., & Bellentani, S. (2018). Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): The available clinical evidence. Nutrients, 10(9). https://doi.org/10.3390/nu10091153
Cicero, A. F. G., Sahebkar, A., Fogacci, F., Bove, M., Giovannini, M., & Borghi, C. (2019). Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: A double-blind, placebo-controlled clinical trial. Eur J Nutr.. https://doi.org/10.1007/s00394-019-01916-7
Dong, J., Xu, H., Xu, H., Wang, P. F., Cai, G. J., Song, H. F., … Jiang, Z. Y. (2013). Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One, 8(12), e83397. https://doi.org/10.1371/journal.pone.0083397
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. Bmj, 315(7109), 629-634.
Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., & Ghayour-Mobarhan, M. (2015). An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial. Chin J Integr Med, 21(5), 332-338. https://doi.org/10.1007/s11655-015-2160-z
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., … Schunemann, H. J. (2011). GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol, 64(4), 383-394. https://doi.org/10.1016/j.jclinepi.2010.04.026
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schunemann, H. J. (2008). GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. Bmj, 336(7650), 924-926. https://doi.org/10.1136/bmj.39489.470347.AD
Hariri, M., & Haghighatdoost, F. (2018). Effect of curcumin on anthropometric measures: A systematic review on randomized clinical trials. J Am Coll Nutr, 37(3), 215-222. https://doi.org/10.1080/07315724.2017.1392263
Higgins, J. P., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., … Sterne, J. A. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj, 343, d5928. https://doi.org/10.1136/bmj.d5928
Higgins, J. P., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. Bmj, 327(7414), 557-560.
Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K., … Hotamisligil, G. S. (2002). A central role for JNK in obesity and insulin resistance. Nature, 420(6913), 333-336. https://doi.org/10.1038/nature01137
Hu, G. X., Lin, H., Lian, Q. Q., Zhou, S. H., Guo, J., Zhou, H. Y., … Ge, R. S. (2013). Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: Improving lipid profiles in high-fat-diet-treated rats. PLoS One, 8(3), e49976. https://doi.org/10.1371/journal.pone.0049976
Jazayeri-Tehrani, S. A., Rezayat, S. M., Mansouri, S., Qorbani, M., Alavian, S. M., Daneshi-Maskooni, M., & Hosseinzadeh-Attar, M. J. (2019). Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): A double-blind randomized placebo-controlled clinical trial. Nutr Metab (Lond), 16, 8. https://doi.org/10.1186/s12986-019-0331-1
Jin, T., Song, Z., Weng, J., & Fantus, I. G. (2018). Curcumin and other dietary polyphenols: Potential mechanisms of metabolic actions and therapy for diabetes and obesity. Am J Physiol Endocrinol Metab, 314(3), E201-e205. https://doi.org/10.1152/ajpendo.00285.2017
Kumari, M., Chandola, T., Brunner, E., & Kivimaki, M. (2010). A nonlinear relationship of generalized and central obesity with diurnal cortisol secretion in the Whitehall II study. J Clin Endocrinol Metab, 95(9), 4415-4423. https://doi.org/10.1210/jc.2009-2105
Lee, Y. K., Lee, W. S., Hwang, J. T., Kwon, D. Y., Surh, Y. J., & Park, O. J. (2009). Curcumin exerts antidifferentiation effect through AMPKα-PPAR-γ in 3T3-L1 adipocytes and antiproliferatory effect through AMPKα-COX-2 in cancer cells. J Agric Food Chem, 57(1), 305-310. https://doi.org/10.1021/jf802737z
Liu, W., Zhai, Y., Heng, X., Che, F. Y., Chen, W., Sun, D., & Zhai, G. (2016). Oral bioavailability of curcumin: Problems and advancements. J Drug Target, 24(8), 694-702. https://doi.org/10.3109/1061186x.2016.1157883
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2012). Multiple antidepressant potential modes of action of curcumin: A review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol, 26(12), 1512-1524. https://doi.org/10.1177/0269881112458732
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001). A transgenic model of visceral obesity and the metabolic syndrome. Science, 294(5549), 2166-2170. https://doi.org/10.1126/science.1066285
Mirhafez, S. R., Farimani, A. R., Dehhabe, M., Bidkhori, M., Hariri, M., Ghouchani, B. F., & Abdollahi, F. (2019). Effect of phytosomal curcumin on circulating levels of adiponectin and leptin in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. J Gastrointestin Liver Dis, 28, 183-189. doi:10.15403/jgld-179
Mirza, M. S. (2011). Obesity, visceral fat, and NAFLD: Querying the role of adipokines in the progression of nonalcoholic fatty liver disease. ISRN Gastroenterol, 2011, 592404. https://doi.org/10.5402/2011/592404
Mohammadi, A., Sahebkar, A., Iranshahi, M., Amini, M., Khojasteh, R., Ghayour-Mobarhan, M., & Ferns, G. A. (2013). Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial. Phytother Res, 27(3), 374-379. https://doi.org/10.1002/ptr.4715
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of internal medicine, 151(4), 264-269.
Mousavi, S. M., Milajerdi, A., Varkaneh, H. K., Gorjipour, M. M., & Esmaillzadeh, A. (2018). The effects of curcumin supplementation on body weight, body mass index and waist circumference: A systematic review and dose-response meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr, 1-10. https://doi.org/10.1080/10408398.2018.1517724
Na, L. X., Li, Y., Pan, H. Z., Zhou, X. L., Sun, D. J., Meng, M., … Sun, C. H. (2013). Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: A double-blind, placebo-controlled trial. Mol Nutr Food Res, 57(9), 1569-1577. https://doi.org/10.1002/mnfr.201200131
Namazi, N., Larijani, B., & Azadbakht, L. (2018). Dietary inflammatory index and its association with the risk of cardiovascular diseases, metabolic syndrome, and mortality: A systematic review and meta-analysis. Horm Metab Res, 50(5), 345-358. https://doi.org/10.1055/a-0596-8204
Navekar, R., Rafraf, M., Ghaffari, A., Asghari-Jafarabadi, M., & Khoshbaten, M. (2017). Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. J Am Coll Nutr, 36(4), 261-267. https://doi.org/10.1080/07315724.2016.1267597
Nieman, D. C., Cialdella-Kam, L., Knab, A. M., & Shanely, R. A. (2012). Influence of red pepper spice and turmeric on inflammation and oxidative stress biomarkers in overweight females: A metabolomics approach. Plant Foods Hum Nutr, 67(4), 415-421. https://doi.org/10.1007/s11130-012-0325-x
Panahi, Y., Khalili, N., Sahebi, E., Namazi, S., Simental-Mendia, L. E., Majeed, M., & Sahebkar, A. (2018). Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled trial. Drug Res (Stuttg), 68(7), 403-409. https://doi.org/10.1055/s-0044-101752
Panahi, Y., Kianpour, P., Mohtashami, R., Jafari, R., Simental-Mendia, L. E., & Sahebkar, A. (2017). Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: A randomized controlled trial. Drug Res (Stuttg), 67(4), 244-251. https://doi.org/10.1055/s-0043-100019
Panahi, Y., Kianpour, P., Mohtashami, R., Soflaei, S. S., & Sahebkar, A. (2018). Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: A clinical study. J Asian Nat Prod Res, 1-8. https://doi.org/10.1080/10286020.2018.1505873
Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., & Sahebkar, A. (2016). Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial. Phytother Res, 30(9), 1540-1548. https://doi.org/10.1002/ptr.5659
Rivera-Espinoza, Y., & Muriel, P. (2009). Pharmacological actions of curcumin in liver diseases or damage. Liver Int, 29(10), 1457-1466. https://doi.org/10.1111/j.1478-3231.2009.02086.x
Saadati, S., Hatami, B., Yari, Z., Shahrbaf, M. A., Eghtesad, S., Mansour, A., … Hekmatdoost, A. (2019). The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr, 73(3), 441-449. https://doi.org/10.1038/s41430-018-0382-9
Shen, P., Han, Y., Cai, B., & Wang, Y. (2015). Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath, 19(2), 515-522. https://doi.org/10.1007/s11325-014-1039-0
Simental-Mendia, L. E., Pirro, M., Gotto, A. M. Jr., Banach, M., Atkin, S. L., Majeed, M., & Sahebkar, A. (2017). Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr, 1-10. https://doi.org/10.1080/10408398.2017.1396201
Wang, S., Wang, X., Ye, Z., Xu, C., Zhang, M., Ruan, B., … Lu, Z. (2015). Curcumin promotes browning of white adipose tissue in a norepinephrine-dependent way. Biochem Biophys Res Commun, 466(2), 247-253. https://doi.org/10.1016/j.bbrc.2015.09.018
Wang, S. L., Li, Y., Wen, Y., Chen, Y. F., Na, L. X., Li, S. T., & Sun, C. H. (2009). Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. Biomed Environ Sci, 22(1), 32-39. https://doi.org/10.1016/s0895-3988(09)60019-2
Williamson, R. M., Price, J. F., Glancy, S., Perry, E., Nee, L. D., Hayes, P. C., … Strachan, M. W. (2011). Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care, 34(5), 1139-1144. https://doi.org/10.2337/dc10-2229
Yang, Y. S., Su, Y. F., Yang, H. W., Lee, Y. H., Chou, J. I., & Ueng, K. C. (2014). Lipid-lowering effects of curcumin in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial. Phytother Res, 28(12), 1770-1777. https://doi.org/10.1002/ptr.5197
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73-84. https://doi.org/10.1002/hep.28431
Zabihi, N. A., Pirro, M., Johnston, T. P., & Sahebkar, A. (2017). Is there a role for curcumin supplementation in the treatment of non-alcoholic fatty liver disease? The data suggest yes. Curr Pharm Des, 23(7), 969-982. https://doi.org/10.2174/1381612822666161010115235
Zhang, D. W., Fu, M., Gao, S. H., & Liu, J. L. (2013). Curcumin and diabetes: A systematic review. Evid Based Complement Alternat Med, 2013, 636053. https://doi.org/10.1155/2013/636053